Viral infection parameters not nucleoside analogue itself correlates with host immunity in nucleoside analogue therapy for chronic hepatitis B

Figure 1 Pretreatment cellular phenotype of patients with chronic hepatitis B. A: Representative dot plots of CD4, CD8, programmed death-1 (PD-1) and FoxP3 staining in chronic hepatitis B (CHB) patients; B: Representative dot plots of CD4, CD8, PD-1 and FoxP3 staining in healthy controls (HCs); C: Peripheral frequency of CD8+ T cells in the CHB patients and HCs; D: Peripheral frequency of CD4+ T cells in the CHB patients and HCs; E: Peripheral frequency of PD-1+ CD8 T cells of the total CD8 T cells in CHB patients and HCs (P = 0.0001); F: Peripheral frequency of PD-1+ CD4 T cells of the total CD4 T cells in CHB patients and HCs; G: Frequency of circulating CD4+CD25+FoxP3+ T cells (FoxP3+ Treg) in the CHB patients and HCs. PBMC: Peripheral blood mononuclear cell.